Ianalumab
CVAY736I12301
Phase 3 mab active
Quick answer
Ianalumab for Primary Immune Thrombocytopenia (ITP) is a Phase 3 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Primary Immune Thrombocytopenia (ITP)
- Phase
- Phase 3
- Modality
- mab
- Status
- active